A controlled clinical trial to evaluate a personalised treatment approach for the management of acute exacerbations (flare-ups) of chronic obstructive pulmonary disease (COPD)
| ISRCTN | ISRCTN85620156 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN85620156 |
| Secondary identifying numbers | CPMS 40057 |
- Submission date
- 28/01/2019
- Registration date
- 01/02/2019
- Last edited
- 03/04/2020
- Recruitment status
- Suspended
- Overall study status
- Completed
- Condition category
- Respiratory
Plain English summary of protocol
Background and study aims
Chronic Obstructive Pulmonary Disease (COPD) is a burdensome, long-term lung disease causing persistent respiratory symptoms and narrowing of the airways. It affects over 10% of people aged over 40. Acute exacerbations of COPD (AECOPD) are symptom flare-ups which cause poor health, hospitalisation or death. They are responsible for 1 in 8 hospital admissions in the UK. While different AECOPD types require different treatments, there are no accurate tests to distinguish them. As a result, all AECOPD are treated the same, with inhaled relievers, to open-up the airways, steroid tablets to treat inflammation, and usually antibiotics to treat infections. However, antibiotics are beneficial only to half of all AECOPD that are caused by bacteria (bugs) and steroid tablets are only effective in 30-50% which are triggered by inflammation in the airways with eosinophils (a special type of white blood cells). Therefore, both steroids and antibiotics are overused, posing unnecessary risks to patients with COPD. For instance, steroids could cause infections or fractures, while antibiotics overuse can lead to the development of dangerous superbugs. Procalcitonin and eosinophils (EOS) are promising blood tests (biomarkers) that could target the use of antibiotics and steroids, respectively, and should be tested in a large clinical trial simulating real-life. This provides a potential opportunity to personalise the management of AECOPD, which could lead to improved use of healthcare resources and a reduction in the frequency of side effects and antibiotic burden (the development of superbugs). The aim of this study is to assess whether the combination of procalcitonin and EOS can identify moderate or severe AECOPD associated with bacterial infection or EOS airway inflammation, and can safely and effectively decrease and target the use of antibiotics and/or steroids. As this is the first study assessing this biomarker combination, only 135 participants are recruited to get an insight into the effects of the intervention and the information needed to launch a larger, confirmatory trial in the future.
Who can participate?
Patients aged over 40 with moderate or severe AECOPD
What does the study involve?
Participants are randomly allocated to receive antibiotic and/or oral steroid treatment guided by biomarkers, or standard courses of antibiotics and oral steroids. All participants receive bronchodilators (inhaled and/or nebulised).
What are the possible benefits and risks of participating?
Participants are assessed more closely for the duration of the study and their COPD treatment will be optimised by experienced members of the research team. In addition, the information collected from this study will help to improve treatment of COPD exacerbations in the future. The study will be the first to assess whether procalcitonin and blood eosinophil count can be used to guide the use of both antibiotics and oral steroids for COPD exacerbations. Therefore, a minority of participants might test negative for both tests and will receive neither antibiotics nor oral steroids. This has not been tested before and there is a risk that it might delay recovery from the exacerbation.
Where is the study run from?
1. Wythenshawe Hospital (lead centre) (UK)
2. Salford Royal Hospital (UK)
When is the study starting and how long is it expected to run for?
December 2018 to September 2021
Who is funding the study?
Boehringer Ingelheim
Who is the main contact?
1. Prof. Jørgen Vestbo
Jorgen.Vestbo@manchester.ac.uk
2. Karen Rhodes
karen.rhodes@mft.nhs.uk
Contact information
Scientific
Division of Infection, Immunity and Respiratory Medicine
University of Manchester
2nd Floor, Education and Research Centre
Wythenshawe Hospital
Southmoor Road
Wythenshawe
M23 9LT
United Kingdom
 ORCID ID |
0000-0001-6355-6362 |
|---|---|
| Phone | +44 (0)161 291 2500 |
| Jorgen.Vestbo@manchester.ac.uk |
Public
Cross Divisional Clinical Trials Manager
Research and Development Directorate
Manchester University NHS Foundation Trust
Wythenshawe Hospital
Southmoor Road
Wythenshawe
M23 9QZ
United Kingdom
| Phone | +44 (0)161 291 5768 |
|---|---|
| karen.rhodes@mft.nhs.uk |
Study information
| Study design | Randomised; Interventional; Design type: Treatment, Process of Care, Complex Intervention, Management of Care, Other |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Characterisation and targeted TReatment of ACute Exacerbations of Chronic Obstructive Pulmonary Disease: the TRACE-COPD randomised controlled trial |
| Study acronym | TRACE-COPD |
| Study objectives | The study hypothesis is that blood eosinophil count and procalcitonin could be used to identify acute exacerbations of chronic obstructive pulmonary diseaes caused by bacteria and those triggered by enhanced eosinophilic airway inflammation and guide the administration of both antibiotics and systemic steroids. |
| Ethics approval(s) | Approved 21/11/2018, North West – Greater Manchester East Research Ethics Committee (3rd Floor, Barlow House, 4 Minshull Street, Manchester, M1 3DZ, Tel: +44 (0)207 104 8009, Email: nrescommittee.northwest-gmeast@nhs.net), ref: 18/NW/0710 |
| Health condition(s) or problem(s) studied | Chronic obstructive pulmonary disease |
| Intervention | For randomisation, the trialists will use randomisation lists independently developed by their in-house biostatisticians. Participants will be stratified according to the recruiting hospital and setting and will be allocated in a 2:1 ratio to the biomarkers or standard care arms. More specifically, the biostatisticians developed four separate lists (one for each hospital and setting), using block sizes of 9. Sequenctially numbered sealed opaque envelopes were created by administrative staff and treatment allocation will be concealed to patients and researchers contributing to recruitment, until informed consent has been obtained. Biomarker-guided treatment arm: A biomarker-guided targeted treatment protocol for AECOPD. Standard courses of antibiotics (doxycycline, 7 days) and/or oral steroids (prednisolone, 5 days) will only be administered for serum procalcitonin levels >0.25μg/L and/or EOS >2%, respectively. Standard care arm: Standard care per NICE guidelines. Standard courses of oral steroids (prednisolone, 5 days) will be administered to all severe exacerbations and to moderate AECOPD characterised by significantly increased breathlessness. Standard courses of antibiotics (doxycycline, 7 days) will be administered to AECOPD associated with a history of more purulent sputum, or clinical or radiographic signs of pneumonia. All participants in both arms will receive bronchodilators (inhaled and/or nebulised). |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Doxycycline, prednisolone |
| Primary outcome measure | 1. The proportion of patients receiving antibiotics for the index exacerbation, evaluated between day 14-21 2. The proportion of patients receiving systemic steroids for the index exacerbation, evaluated between day 14-21 3. Acceptability of the intervention (qualitative data collected throughout the study and during focus group meetings with participants), recruitment and consent rate (evaluated at baseline) |
| Secondary outcome measures | 1. Treatment failure at day 14. Treatment failure will be defined as lack of treatment success, significant symptoms deterioration leading to unplanned healthcare utilisation, or the clinical need for administration of additional antibiotics and/or systemic corticosteroids, or death by day 14 2. Time-to-treatment success, evaluated at day 14-21. Treatment success will be defined as the first day of three consecutive days when the patient will have returned to his normal health state or the first of seven consecutive days in which the patient will only report minor increase in symptoms compared to baseline, without fever or altered sputum color 3. Re-exacerbation rate and re-hospitalisation rate at 6 months 4. Mortality during the index exacerbation (before treatment success, to be evaluated between day 14-21) and at 6 months 5. Adverse events and serious adverse events, evaluated at day 14 6. Increased length of admission or (re-)admission due to side effects to study medications, evaluated at day 14-21 7. Adherence to the intervention by clinicians and patients, evaluated at day 14-21 8. The proportion of patients testing negative to both biomarkers (evaluated at baseline) and the safety of the intervention in this subgroup [see secondary outcomes 1-4] 9. Sample size for a future confirmatory trial, evaluated at day 14-21 10. Feasibility and challenges of community recruitment of patients with acute exacerbations of COPD, evaluated at baseline 11. Resources required for a future, confirmatory trial, including clinic rooms, time investment in the progamme by the study clinicians, evaluated at 6 months 12. Researchers’ and participants’ feedback on the study experience, challenges in the conduction of the study and selected outcomes, collected throughout recruitment 13. Systemic and exhaled biomarkers in different clusters of COPD exacerbations (biomarkers collected in every face-to-face meeting for the duration of the trial) 14. Bacterial and viral presence and load in different AECOPD clusters (samples collected in every face-to-face meeting for the duration of the trial) |
| Overall study start date | 10/12/2018 |
| Completion date | 30/09/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | Planned Sample Size: 135; UK Sample Size: 135 |
| Key inclusion criteria | 1. Males or females aged > 40 years 2. With a smoking history of at least 10 pack-years 3. A previous clinical diagnosis of COPD 4. Presenting with a moderate or severe AECOPD 5. Not having received antibiotics or systemic steroids during the preceding two weeks. 6. Capable of giving an informed consent 7. Subjects who are willing to allow his/her general practitioner, to be notified of their participation in the study. 8. The study will define severe exacerbations as those requiring hospitalisation, based on NICE criteria and moderate as those requiring antibiotics and/or systemic steroids, but not hospitalisation, according to the judgement of the responsible clinician who will be unaware of procalcitonin and EOS levels (following NICE guidelines) |
| Key exclusion criteria | 1. Patients who have already received antibiotics or systemic steroids during the 2 weeks preceding recruitment/randomisation to the TRACE-COPD study 2. Those presenting with decompensated type 2 respiratory failure, requiring non-invasive ventilation and those admitted to the intensive care unit upon presentation 3. Patients with a primary diagnosis of pneumonia 4. Patients with a current diagnosis of asthma 5. Patients with known immunodeficiencies, cystic fibrosis, active tuberculosis, clinically significant bronchiectasis, those receiving long-term antibiotics and those with life expectancy of less than a year 6. People not able or keen to provide an informed consent for the study 7. Female participants who are pregnant or lactating 8. Patients diagnosed with medullary thyroid carcinoma (as this secretes procalcitonin) 9. Participants in active clinical trials of investigational medicinal products (IMP) or people who participated in clinical trials of IMP during the preceding 6 months. We will not recruit patients participating in any trial on COPD exacerbations 10. Patients with known allergy or sensitivity to doxycycline or prednisolone or an absolute contra-indication to their use 11. Patients in active clinical trials of investigational medicinal products (IMP) or people who participated in clinical trials of IMP during the preceding 6 months 12. Patients participating in any trial on COPD exacerbtaions |
| Date of first enrolment | 12/02/2019 |
| Date of final enrolment | 20/09/2019 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Southmoor Road
Manchester
M23 9LT
United Kingdom
Stott Lane
Salford
M6 8HD
United Kingdom
Sponsor information
Hospital/treatment centre
c/o Dr Sian Hanison
Research and Development Directorate
Manchester University NHS Foundation Trust
Wythenshawe Hospital
Southmoor Road
Wythenshawe
M23 9QZ
England
United Kingdom
| Phone | +44 (0)161 291 5777 |
|---|---|
| Sian.hanison@manchester.ac.uk | |
"ROR" |
https://ror.org/00he80998 |
Funders
Funder type
Industry
Private sector organisation / For-profit companies (industry)
- Alternative name(s)
- Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, BI, BIPI
- Location
- United States of America
Results and Publications
| Intention to publish date | 15/02/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Stored in repository |
| Publication and dissemination plan | The study protocol and statistical analysis plan will be published in a peer review journal by September 2019. The trialists aim to present their results in national and international congresses and to publish them in high-impact peer reviewed journals. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study will be stored in a non-publically available repository, the COPD research team pages of the Centre for Respiratory and Allergy Research website (http://research.bmh.manchester.ac.uk/respiratoryandallergy/Research/COPD). All subjects participating in the TRACE-COPD study will be consented specifically for future sharing of anonymised study data. The trialists will facilitate sharing of fully anonymised data with other researchers who provide a methodologically sound proposal. The data will be available for 12 years, following a 3-year period of exclusivity, that will allow those contributing to make full use of the data. The datasets will include all clinical data collected for the TRACE-COPD trial, as well as the levels of all biomarkers that will be measured. Data will be available for 15 years. The data repository will have a Steering Committee comprising the Chief Investigator, the Head of the Division of Infection, Immunity and Respiratory Medicine, a Research and Development Manager and a Biostatistician. The Steering Committee will meet quarterly to consider applications for access to data. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
02/04/2020: The following changes were made to the trial record:
1. Due to current public health guidance, recruitment for this study has been paused.
2. The overall trial end date was changed from 31/03/2020 to 30/09/2021.
3. The intention to publish date was changed from 21/12/2020 to 15/02/2022.
22/03/2019: The condition has been changed from "Specialty: Injuries and Emergencies, Primary sub-specialty: Pre-hospital and Emergency Department Care; Health Category: Respiratory; Disease/Condition: Chronic lower respiratory diseases" to "Chronic obstructive pulmonary disease" following a request from the NIHR.
